Pricing of monoclonal antibody therapies: higher if used for cancer?

CONCLUSIONS: The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states.
PMID: 29461857 [PubMed - in process]

Source: The American Journal of Managed Care - February 1, 2018 Category: Health Management Authors: Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, Shrank WH Tags: Am J Manag Care Source Type: research